(Albany, United States) As per DelveInsight’s assessment, globally, the Lyme Disease pipeline constitutes 7+ key companies continuously working towards developing 7+ Lyme Disease treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight.
In the Lyme Disease Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Lyme Disease clinical trials studies, Lyme Disease NDA approvals (if any), and product development activities comprising the technology, Lyme Disease collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
To explore more information on the latest breakthroughs in the Lyme Disease Pipeline treatment landscape of the report, click here @ Lyme Disease Pipeline Outlook
Key Takeaways from the Lyme Disease Pipeline Report
- DelveInsight’s Lyme Disease Pipeline analysis depicts a robust space with 7+ active players working to develop 7+ pipeline treatment therapies.
- The leading Lyme Disease Companies working in the market include Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, Pfizer, Pharmahungary Group, Iqvia Pty Ltd, Celerion, Takeda, and others
- Promising Lyme Disease Pipeline Therapies in the various stages of development include 2217LS, VLA15, 0.9% Sodium Chloride (NaCl), and others
- On June 2023, Pfizer announced a study of phase 3 clinical trials for VLA15 and normal saline. This study is to understand if the study vaccine (called VLA15) is safe in healthy children.
- On April 2023, Pfizer announced a study of phase 1 clinical trials for VLA15 with Alum. Observer-blind, partially randomized, multi-center dose escalation Phase I study in healthy adults below 40 years of age. In the Main Study Phase a total of 246 subjects were randomized 2:2:1 into three treatment groups to receive either VLA15 with Alum (lower or higher dose) or Placebo. Main Study Phase vaccinations were administered as intramuscular injections on Day 1, Day 57 and Day 180.
Lyme Disease Overview
Lyme disease is the most common vector-borne disease in the United States. Lyme disease is caused by the bacterium Borrelia burgdorferi and rarely, Borrelia mayonii. It is transmitted to humans through the bite of infected blacklegged ticks. Typical symptoms include fever, headache, fatigue, and a characteristic skin rash called erythema migrans.
To explore more information on the latest breakthroughs in the Lyme Disease Pipeline treatment landscape of the report, click here @ https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight
Lyme Disease Emerging Drugs Profile
- VLA 15: Valneva
- CT38: Cortene
Lyme Disease Pipeline Therapeutics Assessment
There are approx. 7+ Lyme Disease companies which are developing the therapies for Lyme Disease. The Lyme Disease companies which have their Lyme Disease drug candidates in the most advanced stage, i.e. phase III include, Valneva.
Request a sample and discover the recent advances in Lyme Disease Ongoing Clinical Trial Analysis and Medications, click here @ https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight
Lyme Disease Drugs and Companies
- 2217LS: MassBiologics/Celerion
- VLA15: Pfizer
Lyme Disease Therapeutics Assessment
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Some of the Companies in the Lyme Disease Therapeutics Market include-
Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, Pfizer, Pharmahungary Group, Iqvia Pty Ltd, Celerion, Takeda, and others
Dive deep into rich insights for drugs for Lyme Disease Pipeline, click here for Lyme Disease Unmet Needs and Analyst Views @ https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight
Scope of the Lyme Disease Pipeline Report
- Coverage- Global
- Lyme Disease Companies- Valneva, Cortene, Blue Lake Biotechnology, Tarsus Pharmaceuticals, Inovio Pharmaceuticals, Aegis Life, Abzyme Therapeutics, Pfizer, Pharmahungary Group, Iqvia Pty Ltd, Celerion, Takeda, and others
- Lyme Disease Pipeline Therapies- 2217LS, VLA15, 0.9% Sodium Chloride (NaCl), and others
- Lyme Disease Segmentation: Product Type, Molecule Type, Route of Administration
Got Queries? Find out the related information on Lyme Disease Merger and acquisitions, Licensing Activities @ https://www.delveinsight.com/sample-request/lyme-disease-ld-pipeline-insight
Table of Content
- Introduction
- Executive Summary
- Lyme Disease: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Lyme Disease – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- VLA 15: Valneva
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- CT 38: Cortene
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Lyme disease vaccine – Introvacc
- Drug profiles in the detailed report…..
- Inactive Products
- Lyme Disease Key Companies
- Lyme Disease Key Products
- Lyme Disease- Unmet Needs
- Lyme Disease- Market Drivers and Barriers
- Lyme Disease- Future Perspectives and Conclusion
- Lyme Disease Analyst Views
- Lyme Disease Key Companies
- Appendix
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services